Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
Jialin Meng, Qintao Ge, Jiawei Li, Xiaofan Lu, Yonghao Chen, Haitao Wang, Meng Zhang, Juan Du, Li Zhang, Zongyao Hao, Chaozhao Liang
Journal of Infection, doi:10.1016/j.jinf.2022.03.020
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis Dear editor, Androgen receptor (AR) is an important transcription factor; thus, androgen and AR-associated pathways play pivotal roles in the progression of several diseases, including prostate cancer (PCa), benign prostatic hyperplasia (BPH), breast cancer, acne, and alopecia [ 1 , 2 ]. Anti-androgen therapy is widely used for the clinical treatment of prostatic diseases, including androgen deprivation therapy (ADT) via surgical castration, pharmacological castration,
Declaration of Competing Interest The authors have no conflicts of interest to declare.
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2022.03.020 .
References
Deng, Rasool, Russell, Natesan, Asangani, Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19, iScience
Leach, Mohr, Giotis, Cil, Isac et al., The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells, Nat Commun
Lyon, Li, Cullen, Milinovich, Kattan et al., 5alpha-reductase inhibitors are associated with reduced risk of SARS-CoV-2 infection: a matchedpair, registry-based analysis, J Urol
Marks, Prasad, Souza, Burns, Senna, Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris, Am J Clin Dermatol
Montopoli, Zumerle, Vettor, Rugge, Zorzi et al., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532), Ann Oncol
Qiao, Wang, Mannan, Pitchiaya, Zhang et al., Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2, Proc Natl Acad Sci
Shukla, Plaga, Shankar, Gupta, Androgen receptor-related diseases: what do we know?, Andrology
Welen, Rosendal, Gisslen, Lenman, Freyhult et al., A phase 2 trial of the effect of antiandrogen therapy on COVID-19 Outcome: No evidence of benefit, supported by epidemiology and in vitro data, Eur Urol
